Ernexa Therapeutics (ERNAW) Operating Leases (2018 - 2026)

Ernexa Therapeutics (ERNAW) has 9 years of Operating Leases data on file, last reported at $226000.0 in Q1 2026.

• Quarterly Operating Leases fell 46.06% year-over-year to $226000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $226000.0 (down 46.06% YoY) and the FY2025 annual result came in at $277000.0, down 59.5% from the prior year.
• Operating Leases fell to $226000.0 in Q1 2026, from $277000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $36.6 million in Q1 2024 to a low of $226000.0 in Q1 2026.
• A 5-year average of $11.0 million and a median of $887000.0 in 2022 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2024 — Operating Leases soared 4247.8% — and 2025, when it tumbled 98.85%.
• Tracing ERNAW's Operating Leases over 5 years: stood at $887000.0 in 2022, then surged by 3603.95% to $32.9 million in 2023, then tumbled by 97.92% to $684000.0 in 2024, then plunged by 59.5% to $277000.0 in 2025, then dropped by 18.41% to $226000.0 in 2026.
• The last three Operating Leases figures came in at $226000.0 (Q1 2026), $277000.0 (Q4 2025), and $552000.0 (Q3 2025), per Business Quant data.